Global Blood
Therapeutics, Inc. (GBT) GBT, a biopharmaceutical company
developing novel therapeutics for the treatment of grievous blood-based
disorders with significant unmet needs, today announced that data from the
ongoing Phase 1/2 GBT440-001 study of GBT440 will be presented at the 57(th)
American Society of Hematology (ASH) Annual Meeting and Exposition in
Orlando, Florida. Data will include an oral presentation of clinical data
from the GBT440-001 study in sickle cell disease (SCD) including data from
SCD patients receiving additional dosing regimens beyond those described in
the abstract, as well as a poster presentation of pharmacokinetic data.
GBT440 is an oral, once-daily therapy for the treatment of SCD that works by
increasing hemoglobin's affinity for oxygen. Since oxygenated sickle
hemoglobin does not polymerize, GBT440 blocks polymerization and the
resultant sickling of red blood cells (RBCs). With the potential to restore
normal hemoglobin function, GBT440 may be capable of modifying the
progression of SCD. Currently, GBT440 is being investigated in an ongoing
Phase 1/2 clinical trial in both healthy subjects and SCD patients.
The abstracts are now available at www.hematology.org. Following are details
of the presentations, which will include additional data not currently
available in the published abstracts.
Oral Session: 114. Hemoglobinopathies, Excluding Thalassemia -- Clinical:
Promising Therapies in Sickle Cell Disease
Abstract #542: GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces
Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral
Blood of Patients with Sickle Cell Disease
Presenter: Dr. Claire Hemmaway, MA (Hons) Cantab, MBBS, FRCP, FRCPATH,
Queens Hospital, Essex, United Kingdom
Session Date: Monday, December 7, 2015
Session Time: 10:30 a.m. -- 12:00 p.m. Eastern Time (ET)
Presentation Time: 10:45 a.m. ET
Location: Orange County Convention Center, W340
Poster Session: 113. Hemoglobinopathies, Excluding Thalassemia -- Basic and
Translational Science: Poster II
Abstract #2172: GBT440 Demonstrates High Specificity for Red Blood Cells in
Nonclinical Species
Session Date/Time: Sunday, December 6, 2015, 6 -- 8 p.m. ET
Location: Orange County Convention Center, Hall A
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in